Certain MicroRNAs Stimulate Regeneration of Adult Heart Tissue
|
By LabMedica International staff writers Posted on 31 Mar 2015 |

Image: An adult cardiomyocyte has re-entered the cell cycle after expression of miR302-367 (Photo courtesy of the laboratory of Dr. Edward Morrisey, University of Pennsylvania).
Cardiac disease researchers working with a mouse model have discovered that by inducing a subset of microRNAs (miRNAs) that are active during development but silenced in the adult they could cause damaged adult heart tissue to regenerate.
The mammalian heart has limited capacity to regenerate after injury in part due to ineffective reactivation of cardiomyocyte proliferation. Investigators at the University of Pennsylvania (Philadelphia, USA) recently found that the microRNA cluster miR302-367 was important for cardiomyocyte proliferation during development and was sufficient to induce cardiomyocyte proliferation in the adult and promote cardiac regeneration. MiRNAs are fragments of RNA about 20 nucleotides long that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The investigators reported in the March 18, 2015, online edition of the journal Science Translational Medicine that in their mouse model loss of miR302-367 led to decreased cardiomyocyte proliferation during development. In contrast, elevated miR302-367 expression led to a profound increase in cardiomyocyte proliferation, in part through repression of the Hippo signal transduction pathway. The Hippo signaling pathway controls organ size in animals through the regulation of cell proliferation and apoptosis. The pathway takes its name from one of its key signaling components, the protein kinase Hippo (Hpo). Mutations in this gene lead to tissue overgrowth, or a "hippopotamus"-like phenotype.
Induced expression of miR302-367 in adult animals reactivated the cell cycle in cardiomyocytes, resulting in reduced scar formation after experimental myocardial infarction. Furthermore, the number of heart muscle cells in these mice was found to increase. However, long-term expression of miR302-367 induced cardiomyocyte dedifferentiation and dysfunction, suggesting that persistent reactivation of the cell cycle in postnatal cardiomyocytes was not desirable. This limitation was overcome by transient systemic application of synthetic microRNAs that mimicked miR302-367, leading to increased cardiomyocyte proliferation and mass, decreased fibrosis, and improved function after injury.
"The Hippo pathway normally represses cell proliferation when it is turned on. The cluster miR302-367 targets three of the major kinase components in the Hippo pathway, reducing pathway activity, which allows cardiomyocytes to re-enter the cell cycle and begin to regrow heart muscle," said senior author Dr. Edward E. Morrisey, professor of medicine and cell and developmental biology at the University of Pennsylvania. "This is a case of repressing a repressor."
"Persistent reactivation of the cell cycle in adult cardiomyocytes could be harmful and causes the heart to fail," said Dr. Morrisey. "We overcame this limitation by injecting synthetic microRNAs with a short half-life called mimics into the mice. The next stage in this study is to determine whether miRNA mimics will work in a larger animal model and to collaborate with bioengineers to create a local delivery system for the heart, rather than giving it systemically."
Related Links:
University of Pennsylvania
The mammalian heart has limited capacity to regenerate after injury in part due to ineffective reactivation of cardiomyocyte proliferation. Investigators at the University of Pennsylvania (Philadelphia, USA) recently found that the microRNA cluster miR302-367 was important for cardiomyocyte proliferation during development and was sufficient to induce cardiomyocyte proliferation in the adult and promote cardiac regeneration. MiRNAs are fragments of RNA about 20 nucleotides long that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The investigators reported in the March 18, 2015, online edition of the journal Science Translational Medicine that in their mouse model loss of miR302-367 led to decreased cardiomyocyte proliferation during development. In contrast, elevated miR302-367 expression led to a profound increase in cardiomyocyte proliferation, in part through repression of the Hippo signal transduction pathway. The Hippo signaling pathway controls organ size in animals through the regulation of cell proliferation and apoptosis. The pathway takes its name from one of its key signaling components, the protein kinase Hippo (Hpo). Mutations in this gene lead to tissue overgrowth, or a "hippopotamus"-like phenotype.
Induced expression of miR302-367 in adult animals reactivated the cell cycle in cardiomyocytes, resulting in reduced scar formation after experimental myocardial infarction. Furthermore, the number of heart muscle cells in these mice was found to increase. However, long-term expression of miR302-367 induced cardiomyocyte dedifferentiation and dysfunction, suggesting that persistent reactivation of the cell cycle in postnatal cardiomyocytes was not desirable. This limitation was overcome by transient systemic application of synthetic microRNAs that mimicked miR302-367, leading to increased cardiomyocyte proliferation and mass, decreased fibrosis, and improved function after injury.
"The Hippo pathway normally represses cell proliferation when it is turned on. The cluster miR302-367 targets three of the major kinase components in the Hippo pathway, reducing pathway activity, which allows cardiomyocytes to re-enter the cell cycle and begin to regrow heart muscle," said senior author Dr. Edward E. Morrisey, professor of medicine and cell and developmental biology at the University of Pennsylvania. "This is a case of repressing a repressor."
"Persistent reactivation of the cell cycle in adult cardiomyocytes could be harmful and causes the heart to fail," said Dr. Morrisey. "We overcame this limitation by injecting synthetic microRNAs with a short half-life called mimics into the mice. The next stage in this study is to determine whether miRNA mimics will work in a larger animal model and to collaborate with bioengineers to create a local delivery system for the heart, rather than giving it systemically."
Related Links:
University of Pennsylvania
Latest BioResearch News
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Distinguishes Deadly Cardiac Events
Two life-threatening cardiovascular emergencies—myocardial infarction and aortic dissection—often present with the same symptom: sudden, severe chest pain. Yet the treatments for these conditions are fundamentally... Read more
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read moreMolecular Diagnostics
view channel
Single Blood Test Predicts Heart Diseases 15 Years Before Onset
Cardiovascular diseases remain the leading cause of death worldwide, claiming nearly 19.8 million lives in 2022 alone. Early identification of individuals at risk is critical for prevention, yet conventional... Read more
New Blood Test Aims to Transform Liver Cancer Surveillance
Liver cancer is one of the fastest‑growing causes of cancer‑related death in the U.S., and surveillance programs face gaps in performance and patient adherence that contribute to late diagnoses.... Read more
Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug
New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more
Clinical Diagnostic Test Detects Additional Genetic Variants in Acute Leukemia Patients
Genetic testing plays a critical role in diagnosing acute leukemia, determining disease subtype, guiding treatment decisions, and predicting patient outcomes. However, traditional diagnostic workflows... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read more
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more








